Skip to main content
SpringerLink
Log in

Lyme Disease Vaccine (Pasteur Mérieux Connaught)

ImuLyme™

  • Section 2: Prophylactic Anti-Infective Vaccines
  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Clinical trial demonstrates Pasteur Mérieux Connaught’s candidate Lyme disease vaccine reduces overall occurrence of lyme disease in participants. [press release]. Pasteur Mérieux Connaught [online]: 1997 Sep 15. Available from: URL: http://www.us.pmc-vacc.com [Accessed 1999 Sep 3]

  2. Sigal LH, Zahradnik JM, Lavin P, et al. Avaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. N Engl J Med 1998 Jul 23; 339: 216–22

    Article  PubMed  CAS  Google Scholar 

  3. Wormser GP, Nowakowski J, Nadelman RB, et al. Efficacy of an OspA vaccine preparation for prevention of lyme disease in New York State. Infection 1998 Jul–Aug; 26: 208–12

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lyme Disease Vaccine (Pasteur Mérieux Connaught). Drugs R&D 2, 211–212 (1999). https://doi.org/10.2165/00126839-199902030-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902030-00015

Keywords

Search

Navigation